{
  "source": "PA-Med-Nec-Slynd.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2185-7\nProgram Prior Authorization – Medical Necessity\nMedication Slynd® (drospirenone)\nP&T Approval Date 1/2020, 7/2020, 4/2021, 1/2022, 2/2023, 2/2024, 9/2024\nEffective Date 11/17/2024\n1. Background:\nOral contraceptives are available as either combination estrogen/progesterone-containing\ncontraceptives or as progesterone-only contraceptives. Progesterone-only contraceptives should\nbe used when estrogen-containing contraceptives are contraindicated. Slynd (drospirenone) is a\nprogesterone-only contraceptive indicated for use by females of reproductive potential to\nprevent pregnancy.\n2. Coverage Criteriaa:\nA. Authorization\n1. Slynd will be approved based on all of the following criteria:\na. Used for the prevention of pregnancy\n-AND-\nb. History of failure, contraindication, or intolerance to both of the following\nprogesterone-only contraceptives\n1) norethindrone (generic Ortho Micronor®)\n2) norgestrel (Opill)\n-AND-\nc. Provider attests that patient has been instructed to avoid estrogen containing\ncontraceptives due to a health concern or the patient is currently breastfeeding\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic\nclass.\n4. References:\n1. Slynd [package insert]. Florham Park, NJ: Exeltis USA, Inc; May 2019.\n2. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for\nContraceptive Use, 2016. MMWR Recomm Rep 2016;6",
    " [package insert]. Florham Park, NJ: Exeltis USA, Inc; May 2019.\n2. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for\nContraceptive Use, 2016. MMWR Recomm Rep 2016;65(No. RR-4):1–66. DOI:\nhttp://dx.doi.org/10.15585/mmwr.rr6504a1\nProgram Prior Authorization – Medical Necessity\nChange Control\n1/2020 New program.\n7/2020 Updated contraindications to include history of breast cancer and\nmigraine with aura.\n4/2021 Simplified contraindication language and added documentation of\ncontraindication.\n1/2022 Annual review. No changes.\n2/2023 Annual review. No changes.\n2/2024 Annual review. Updated criteria to note a progesterone-only\ncontraceptive due to the approval of the over-the-counter contraceptive.\n9/2024 Require failure of two progestin only contraceptives, removed estrogen\nfailure and updated prescriber attestation statement. Reauthorization\nremoved.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}